ABSTRACT
Herpes zoster (HZ) may have atypical clinical presentations, particularly in immunosuppressed patients. Nodular HZ is an extremely rare condition. We report the first case of recurrent papulonodular HZ in an adult patient with inflammatory bowel disease (IBD) receiving biologic treatment. More interestingly, there was no epidermal involvement on histopathological examination, but the involvement of the adnexa and blood vessels was a clue to the diagnosis in view of the clinical context. We wish to raise awareness of this rare manifestation of HZ for early diagnosis and proper treatment.
Subject(s)
Folliculitis , Herpes Zoster , Vasculitis , Adult , Humans , Herpes Zoster/complications , Herpes Zoster/diagnosis , Herpes Zoster/pathology , Herpesvirus 3, Human , Folliculitis/diagnosis , Folliculitis/pathologySubject(s)
Castleman Disease , Paraneoplastic Syndromes , Pemphigus , Female , Humans , Pemphigus/etiology , Paraneoplastic Syndromes/etiologyABSTRACT
BACKGROUND: Primary cutaneous amyloidosis (PCA) and post-inflammatory hyperpigmentation (PIH) are common causes of cutaneous hyperpigmentation that are usually diagnosed clinically. However, their presentations are sometimes atypical, and their differentiation is difficult. Dermoscopy is a valuable diagnostic tool for pigmented diseases that might aid in their diagnosis. OBJECTIVE: To describe the characteristic dermoscopic features of PCA and PIH together with histopathological correlation, and to differentiate between these conditions in a non-invasive way. METHODS: Fifty-two patients with PCA (n = 26) and PIH (n = 26) were enrolled. A detailed history, skin examination, dermoscopic examination using handheld and video dermoscopy, and histopathological evaluation were performed. RESULTS: A statistically significant difference could be detected between PCA and PIH in terms of the duration of the disease (p = 0.027), symmetry (p = 0.044), rippling (p < 0.001), and back affection (p = 0.048). On dermoscopic examination, central hubs were seen more in the PCA group (p < 0.001) with different patterns of peripheral pigmentation. Histopathologically, the number of melanophages per high-power field was significantly higher in the PCA group (p = 0.013). CONCLUSION: The results of this study shed the light on the potential of dermoscopy as a non-invasive diagnostic tool in differentiating between doubtful cases of PCA and PIH.
Subject(s)
Amyloidosis , Hyperpigmentation , Skin Neoplasms , Humans , Dermoscopy/methods , Hyperpigmentation/diagnostic imaging , Hyperpigmentation/etiology , Skin Neoplasms/pathologySubject(s)
Eczema , Hamartoma , Nevus , Skin Neoplasms , Eccrine Glands , Humans , Nevus/complications , Nevus/diagnosis , Skin Neoplasms/complications , Skin Neoplasms/diagnosisABSTRACT
BACKGROUND: The treatment of atrophic acne scars represents a therapeutic challenge. Recently, plasma gel has been introduced among treatment modalities. OBJECTIVE: To compare the efficacy of platelet-rich-plasma 'fluid' versus 'gel' form combined with fractional CO2 laser in the treatment of atrophic acne scars. METHODS: Twenty-seven patients with atrophic acne scars were included. Treatment with fractional CO2 laser plus plasma fluid/gel was randomly assigned to the right/left sides of the face. Clinical and Optical Coherence Tomography (OCT) assessments were scheduled at baseline, one month, and three months after the last session. RESULTS: There was a significant improvement in clinical assessment scores at third-month follow-up on the plasma gel- and plasma fluid-treated sides compared to those at the first-month follow-up (p < .001). Scar depth decreased significantly at third-month follow-up when compared to baseline on both plasma gel- and plasma fluid-treated sides (p < .001). The numerical pain score was significantly lower on the plasma fluid-treated side compared to the plasma gel-treated side (p = .004). CONCLUSION: The use of platelet-rich plasma in combination with fractional CO2 laser, both in fluid and gel form, produced significant results in the treatment of atrophic acne scars. Patients reported an immediate more noticeable effect with plasma gel. However, the fluid injection was less painful.
Subject(s)
Acne Vulgaris , Lasers, Gas , Platelet-Rich Plasma , Acne Vulgaris/complications , Acne Vulgaris/therapy , Atrophy/etiology , Carbon Dioxide , Cicatrix/etiology , Cicatrix/pathology , Cicatrix/therapy , Humans , Lasers, Gas/therapeutic use , Patient Satisfaction , Treatment OutcomeABSTRACT
Cutaneous leukocytoclastic vasculitis (LCV) has been reported as a rare form of cutaneous reaction to different SARS-Cov-2 vaccines. Herein, we present the first case of cutaneous LCV following BBIBP-CorV (Sinopharm) vaccine that occurred in a female patient with no prior comorbidities. A literature review about similar cases following different COVID-19 vaccines is discussed.
Subject(s)
COVID-19 , Vasculitis, Leukocytoclastic, Cutaneous , COVID-19 Vaccines , Female , Humans , SARS-CoV-2 , Vasculitis, Leukocytoclastic, Cutaneous/chemically inducedABSTRACT
BACKGROUND: Histone deacetylase 1 (HDAC1) belongs to class I histone deacetylases, which are zinc-dependent enzymes that remove the acetyl group from histones and other proteins providing epigenetic regulation of gene expression. It plays an important role in the hair follicle and epidermal homeostasis in addition to its immunomodulatory roles. Alopecia areata (AA) and acne vulgaris are common skin diseases in which epigenetic factors have been proposed. However, studies of epigenetic modifications in both diseases are quite limited. OBJECTIVE: This study aimed at elucidation of HDAC1 deregulation in AA and acne vulgaris. METHODS: A case-control study was conducted on 76 participants: 25 patients with patchy alopecia areata, 26 patients with acne vulgaris and 25 healthy controls. Blood samples were collected for the measurement of HDAC1 level by ELISA. RESULTS: A significant difference in the serum level of HDAC1 was found between the studied groups being highest in the AA group (P = 0.0001). It was significantly higher in the AA group than the acne vulgaris group (P = 0.0001). CONCLUSION: HDAC1 appears to be deregulated in patients with AA and acne vulgaris. This may suggest a potential therapeutic opportunity for HDAC inhibitors for the treatment of such diseases.
Subject(s)
Acne Vulgaris , Alopecia Areata , Epigenesis, Genetic , Histone Deacetylase 1 , Acne Vulgaris/drug therapy , Acne Vulgaris/genetics , Alopecia Areata/drug therapy , Alopecia Areata/genetics , Case-Control Studies , Histone Deacetylase 1/genetics , HumansABSTRACT
BACKGROUND: Pemphigus vulgaris (PV) is a debilitating autoimmune blistering disease of the skin and mucous membranes. It occurs due to the action of autoantibodies against various keratinocyte self-antigens. Anti-mitochondrial autoantibodies are detected in patients with PV. Coenzyme Q10 (CoQ10) is a member of the mitochondrial respiratory chain involved in cellular metabolism, including apoptosis. This study aimed to assess the serum and tissue levels of CoQ10 of patients with PV and healthy controls to determine its relevance to the disease pathogenesis. METHODS: In this case-control study, 20 patients with PV and 20 healthy controls were included. Blood and skin samples were collected for the measurement of CoQ10 levels using ELISA. RESULTS: CoQ10 was significantly lower in both serum and tissue of patients with PV compared with controls (p = 0.001). Similar results were found when gender subgroups were separately compared. A significant positive correlation was found between serum and tissue CoQ10 levels in controls (p = 0.019, r = 0.521), but not in patients with PV. CONCLUSION: CoQ10 appears to be one of the parameters affected by the autoimmune response in PV, which may contribute to the tissue damage caused by autoantibodies. The absence of a significant correlation between CoQ10 level and disease severity or duration may be caused by the complex pathophysiological process in PV with multiple autoantibodies against different keratinocyte antigens.
Subject(s)
Pemphigus , Autoantibodies/metabolism , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Humans , Pemphigus/pathology , Ubiquinone/analogs & derivativesABSTRACT
The Coronavirus disease 2019 (COVID-19) pandemic spreads quickly all over the world. There are no sufficient data in the literature about COVID-19 infection and cutaneous lymphomas. This review sheds the light on what is known so far about COVID-19 with a cutaneous lymphoma perspective. Cutaneous T-cell lymphoma (CTCL) diagnosis does not represent a predisposing factor to viral infections and most of CTCL patients have indolent disease. However, physicians should be cautious with patients with aggressive primary cutaneous lymphomas and advanced CTCL. Different treatment strategies for cutaneous lymphomas should be taken into consideration during the COVID-19 pandemic. Thus, it is highly needed to estimate the benefit-to-risk ratio on a case-by-case basis.